Horses were immunized by a variety of inoculation procedures designed to determine the most efficient method of producing antisera to adenovirus types 25 to 31. The procedures evaluated included immunization by (i) direct intravenous (iv) injection, (ii) iv infusion, (iii) intramuscular (im) injection of virus with and without Freund's incomplete adjuvant, (iv) combined iv and im injections, and (v) combined iv infusion and im injection. The im schedule (no. 3) was superior to the others in terms of immunizing antigen and time required, and hemagglutination-inhibition (HI) and serum-neutralizing (SN) antibody levels produced. HI and SN tests performed with sera before and after heating at 56 C for 30 min showed that heat-inactivation was not necessary for tests with equine antisera.
Adenovirus (AV) antisera have usually been prepared in rabbits by multiple intravenous (iv) inoculations. This method has worked well for the first 18 AV serotypes (14, 15, (18) (19) (20) (21) (22) but has been less efficient for the remaining 13 types (16) (17) (18) 21) . In addition, the necessity of pooling the serum of many rabbits to obtain a sufficient volume of antiserum to a single type is laborious and results in a product which may be of less than optimal quality. To circumvent these problems, Lucas et al. (13) prepared antisera to types 1 to 18 in horses by giving multiple iv injections, usually five inoculations of 40 ml each, at weekly intervals and exsanguinating the animals 14 days after the last injection. This procedure resulted in large volumes (approximately 10,000 ml per horse) of specific antisera with acceptable homologous antibody titers.
In continuing the production of equine antisera to the human AV, we have found that iv injection does not result in acceptable levels of antibodies to the higher-numbered types (types 25 to 31). In this report we describe a procedure which is superior to the iv schedule and which should be applicable for production of equine antisera to other viruses as well.
MATERIALS AND METHODS
Production of immunizing antigen (IA). Prototype strains of AV types 25 through 31 were obtained from the Research Resources Branch (RRB) of the National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), Bethesda, Md. Stock viruses were propagated in HEp-2 human epithelium cell cultures grown on Eagle's minimum essential medium (MEM) with 10% fetal calf serum, and maintained on MEM without serum. For production of immunizing antigens, cell monolayers in 32-oz (ca. 0.946 liter) prescription bottles were washed twice with Hanks balanced salt solution and inoculated dry with 3 to 4 ml of stock virus containing approximately 106 median tissue culture infective doses (TCID,0) per 0.1 ml. After a 2-hr adsorption period at 35 C, 26 ml of serum-free, antibiotic-free maintenance medium was added to each bottle. The cultures were observed daily and then frozen 2 days after development of complete cytopathology (CPE). The virus and viral components were harvested after four freeze-thaw cycles followed by a low-speed centrifugation (1,000 x g, 30 min) to remove cellular debris. The supernatant fluid served as the immunizing antigen.
Determination of purity. The product prepared for horse immunization was comprehensively tested for bacterial, fungal, and mycoplasmal sterility; 1.5 ml of the product was inoculated into Trypticase soy and thioglycolate broths, neopeptone infusion agar streak/pour plates with 5% defibrinated sheep blood, Sabouraud glucose agar, and PPLO agar. All media were kept for 21 days at 37 C. Breakthrough neutralization tests to detect contamination by other complete viruses were performed as described by Hampil and Melnick (6) . In this test, the culture was consid-ered pure if all breakthrough viruses were neutralized at serum dilutions equivalent to the known homologous titers of reference NIH (RRB) antisera. Complement fixation (CF) tests to detect contamination by the AV-associated viruses (AAV types [1] [2] [3] [4] were performed with prototype antisera (2, 11 Immunization methods. A variety of immunization preparations and methods were used for intramuscular (im) and iv routes. In method A (iv), 40 ml of immunizing antigen was given by direct intrajugular inoculation. In method B (iv-drip), 40 ml of IA was diluted into 4,000 ml of cold, sterile PBS in an aspirator bottle packed in wet ice. The solution was passed under restricted gravity flow over an 18-hr period through an indwelling catheter in the jugular vein. If necessary, horses were tranquilized with an im injection of 250 mg of promazine-hydrochloride. In method C (im), 20 ml of IA was given im, 5 ml in each of two sites in the hindquarters (gluteus medius muscles) and in each of two sites in the pectoral muscles. In method D (im-FICA), 20 ml of IA was vigorously mixed with an equal volume of Freund's incomplete adjuvant (FICA; Difco Laboratories, Detroit). The emulsion was mixed in an International PR-IH centrifuge equipped with an IEC shaker head (no. 6007) and operated at 1,000 rev/min for 30 min at 4 C. Although the emulsion thus prepared was completely stable for weeks, fresh material was prepared for each injection. An injection consisted of 40 ml of the mixture, 10 ml in each of two sites in the muscles of the hindquarters and in each of two sites in the pectoral muscles.
RESULTS
Evaluation of immunizing antigens. The immunizing antigens of AV types 25 to 31 were thoroughly tested for purity, potency, and specificity as described above. All products were free from bacterial, fungal, and mycoplasmal contaminants. Contamination of the IA by other complete viruses or by AAV was not detected by breakthrough neutralization and CF tests, respectively.
Biological data on the IA are presented in Table 1 . The 14-day infectivity titers are somewhat lower than usual because the IA cultures were incubated well beyond the point of optimal infectivity to attain maximal concentrations of CF and HA antigens. Identity of the IA was shown by homologous HI and SN tests with reference antisera. In all cases, HI and SN titers obtained with the IA were equivalent to the known serum titers obtained with reference virus stocks. Identification of the breakthrough viruses from breakthrough neutralization tests was also confirmed by HI and SN tests performed in parallel with reference virus stocks. Again, equivalent titers were obtained. All IA were thus shown by our criteria to be acceptable for horse inoculation.
Total protein concentration of the 7 IA preparations was 697 to 833 (average 758) gg/ml. Of this, 85 to 115 (average 100) qg/ml was estimated to be virus and viral component protein. Evaluation of immunizing schedules. All horses were pretested for absence of antibody to all 31 human AV types. Antibody-free horses were then randomly divided into five immunization schedules or were assigned to one or another schedule for a particular AV type.
The schedules are summarized in Table 2 . Schedule 1 was the control schedule and consisted of five iv inoculations (method A) of 40 ml each, at 1-or 2-week intervals; if necessary, these inoculations were followed by an 80-ml booster after 7 weeks. Schedule 2 used the ivdrip (method B) only; the inoculations were given on days 0, 3, 7, and 10.
Schedule 3 called for im method D on day 0, and im method C on days 14 and 21. Schedule 4 was the combined im/iv schedule: an im-FICA inoculation (method D) on day 0, 20 ml im (method C) and 40 ml iv (method A) on day 14; 40 ml iv on day 17; 20 ml im and 40 ml iv on day 21; and 40 ml iv on day 24.
Schedule 5 was the combined im/iv-drip schedule: an im-FICA inoculation (method D) on day 0; 20 ml im (method C) and 4,000 ml iv-drip (method B) on day 14; 4,000 ml iv-drip on day 17; 20 ml im and 4,000 ml iv-drip on day 21; and 4,000 ml iv-drip on day 24.
Since it was not feasible to evaluate all schedules with all seven AV types, types 25 and 28 were first used to compare schedules 1, 3, and 5 ( Table 3) . The HI and SN titers listed show several unequal qualities for the three schedules. The HI titers for AV 25 and 28 developed first with schedule 5 and were quite delayed in schedule 3; yet the final HI titers were virtually identical for all three schedules. SN titers for both AV 25 and 28 also developed The results with schedule 3 supported our long-term experience in immunizing rabbits with various AV serotypes by the im route (7, 8) . It therefore appeared that the im route alone was superior to either iv method previously used. To confirm this hypothesis, we compared the efficiency of im and iv routes, used alone and in combination, in eliciting HI and SN antibody to AV-29. Type 29 was chosen because of its poor antibody response in rabbits and its significant cross-'reactions with types 15 and 23 in the SN test (17, 18, 22) . We felt that the deliberate choice of one of the more "difficult" AV types would provide a better test of the im hypothesis than a type which traditionally has given good antibody responses and which is free of troublesome cross-reactions.
Comparative HI and SN antibody titers in eight horses inoculated with AV-29 by schedules 2, 3, 4, 5 are presented in Table 4 . Two horses were assigned at random to each of the four schedules. Schedule 2 was unsuccessful as seen by the poor HI response and by the absence of SN response. Schedules 3, 4, and 5, all of which contained the im schedule (no. 3), were approximately equal by both HI and SN. Schedule 3, however, consistently gave the highest HI and SN antibody responses in both horses. Reference equine antiserum to AV-29 was therefore obtained from one of the schedule 3 horses (no. 6), which was exsanguinated on day 35. Continuing interval bleedings of the remaining horses up to 70 days after initial inoculation showed a gradual decline in antibody levels. Hence an immunization period of 28 to 38 days (Tables 3,4) appeared to be optimal for the production of high-titered antisera.
The im schedule (no. 3) was then used to produce the remaining antisera in the AV-25 through AV-31 series ( Table 5 ). The HI and SN antibody levels obtained in the final serum samples are all equal to or, in most cases, higher than the comparable titers in the reference rabbit antisera (Table 1) . This supports the superiority of the im route over the iv route, especially since the equine serum titers of the first 18 AV types (13) were generally lower than the equivalent titers in rabbits (18, 19) .
Throughout this study, HI and SN titers on final serum samples were identical in unheated sera and in sera which had been heat-inactivated at 56 C for 30 min. Only 7-to 14-day serum samples showed differences in titer for unheated and heated sera; the unheated serum often exhibited higher titers than the heated serum (Table 4) . This effect was shown previously to be the result of broadly-specific immunoglobulin M (IgM) or "early" antibody (1, 7) . DISCUSSION The production of reference equine antisera to the human AV has been a function of our laboratory for many years. The earlier AV types (1 to 18) elicited suitable HI and SN antibody responses in horses when the antigens were injected iv in multiple 40-ml volumes a HI titers of antisera 25 through 30 were determined with rat RBC; AV-31 does not agglutinate any RBC and therefore the homologous antiserum does not have a detectable HI titer. All HI and SN titers are listed as reciprocal of end-point dilution (see Table 3 , footnotes a and b).
b O = <10. c Underscored numbers are titers of the frozen, pre-lyophilized antisera. The consistent observation that the combined im/iv and combined im/iv-drip methods produced slightly lower HI and SN titers than the im method alone may be a consequence of the time of serum sampling in relation to the last iv injection. A portion of the specific serum antibodies might be bound by the iv virus and subsequently removed from the circulating blood by the host's immunological clearance systems. This would tend to lower the serum antibody titers temporarily, and might permanently depress the host's response to the antigen.
Heat-inactivation (56 C, 30 min) of the equine antisera evaluated in this study had no apparent effect on HI or SN antibody titers. As expected, early sera drawn 7-to 14-days after primary inoculation often contained elevated IgM levels which were detectable in unheated sera by both tests. But sera drawn later than the 14th day after primary inoculation contained identical titers in heated and unheated serum samples. This supports our extensive observations that equine antisera do not contain nonspecific inhibitors or complement components in sufficient levels to affect HI or SN antibody titers. Hence heat-inactivation of equine antisera for AV serology appears to serve no useful purpose, and may in fact destroy heat-labile factors that could be essential (4, 23) .
The im immunization schedule (no. 3) described in this report is superior in many ways to the iv routes evaluated. (i) It is simpler to perform since it uses only three inoculationsone with adjuvant, two without. (ii) It requires smaller amounts of antigen than do the iv routes: 60 ml, at an average of 100 ,ug of viral protein per ml (approximately 6,000 total lug of viral protein per horse) compared with 200 to 280 ml (20,000 to 28,000 total ,ug of viral protein) for the iv schedule. (iii) It requires only 28 to 38 days and could thereby minimize heterotypic antibody responses. (iv) It results in high-titered specific antisera. We hope that this procedure will be applied to the production of antisera to new AV serotypes as well as to other viruses and organisms with low immunizing potential in large animals.
